- |||||||||| Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
Enrollment closed, Viral vector: A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) - May 3, 2020 P2, N=10, Active, not recruiting, NCT01560182, https://clinicaltrials.gov/ct2/show/NCT01560182; EudraCT # 2009-017349-77 Trial 2: OTL-200-c: A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD); NCT03392987, https://clinicaltrials.gov/ct2/show/NCT03392987 Recruiting --> Active, not recruiting
- |||||||||| Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
Phase classification, Enrollment change, Trial primary completion date, Gene therapy: TIGET-MLD: Gene Therapy for Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) - Dec 20, 2018 P1/2, N=20, Active, not recruiting, NCT01560182, https://clinicaltrials.gov/ct2/show/NCT01560182; EudraCT # 2009-017349-77 Trial 2: OTL-200-c: A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD); NCT03392987, https://clinicaltrials.gov/ct2/show/NCT03392987 Phase classification: P2 --> P1/2 | N=14 --> 20 | Trial primary completion date: Apr 2023 --> Apr 2018
- |||||||||| Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
Phase classification, Enrollment change, Trial primary completion date, Gene therapy: TIGET-MLD: Gene Therapy for Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) - Mar 24, 2017 P2, N=14, Active, not recruiting, Phase classification: P3 --> P2 Phase classification: P1/2 --> P2 | N=20 --> 14 | Trial primary completion date: Apr 2018 --> Apr 2023
- |||||||||| Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
Enrollment closed, Trial primary completion date, Gene therapy: TIGET-MLD: Gene Therapy for Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) - Apr 21, 2015 P1/2, N=20, Active, not recruiting, Phase classification: P1/2 --> P2 | N=20 --> 14 | Trial primary completion date: Apr 2018 --> Apr 2023 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Apr 2018
- |||||||||| Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
Enrollment status, Trial primary completion date, Gene therapy: TIGET-MLD: Gene Therapy for Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) - Dec 9, 2014 P1/2, N=20, Enrolling by invitation, Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Apr 2018 Recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2015 --> Oct 2017
|